Abstract-Early
T raditional strategies for the treatment of coronary artery disease (CAD) are aimed at restoring flow in coronary arteries with obstructive atherosclerotic lesions and are the basis for millions of percutaneous coronary interventions (PCI) and coronary artery bypass grafting procedures performed each year. Although this approach reduces ischemic burden and relieves angina symptoms, it does not prevent many acute coronary syndromes (ACS). ACS is frequently caused by plaque rupture of nonobstructive, eccentric coronary plaques, which initiates a thrombotic cascade leading to (near) total occlusion of the coronary lumen. 1 Consequently, an ACS with potentially devastating effects is frequently the initial presentation of CAD in previously asymptomatic patients. These observations have raised interest in the early identification and treatment of high-risk coronary artery lesions, or so-called vulnerable plaques, to prevent future ACS. [1] [2] [3] This review aims to give an update on the definition, detection, and treatment of the vulnerable plaque.
Atherosclerosis and ACS Plaque Formation
CAD is a chronic disease, in which over the course of decades, inflammation of the coronary vessel wall can lead to the formation of complex atherosclerotic lesions. 1, 4, 5 Histological studies on the pathogenesis of atherosclerosis have provided clear insight into the various stages of coronary plaque formation. First, accumulation of low-density lipoprotein (LDL) particles in the intima of the arterial vessel wall lead to pathological intimal thickening, by acting as a chronic stimulator of the innate and adaptive immune response. 1 Histologically, this is characterized by the presence of smooth muscle cell remnants within an extracellular matrix composed of proteoglycans and collagen type 2, coinciding with small, extracellular lipid pools beneath layers of foam cells. Subsequently, macrophage infiltration within lipid pools and subsequent necrosis and apoptosis of these macrophages results in the formation of a demarcated acellular and lipid-rich necrotic core, which is encapsulated by surrounding fibrous tissue. This progressivetype lesion is defined as a fibroatheroma. Calcification can occur in all stages of progressive atherosclerosis. 1, 4, 5 
Mechanisms for ACS
In general, ACS is caused by the formation of an intracoronary thrombus superimposed on an atherosclerotic lesion, except for rare cases such as spontaneous coronary artery dissection and coronary vasospasm. Three distinct pathophysiological mechanisms have been described that may lead to Detection and Treatment of Vulnerable Plaques intracoronary thrombus formation: plaque rupture, plaque erosion, and calcified nodule. 2, 4, 6 Plaque rupture is defined as a defect or gap in the overlying cap of the fibroatheroma that leads to exposure of its highly thrombogenic contents to the blood and subsequently followed by rapid thrombus accumulation at the site of rupture. 2 The pathogenesis of ACS associated with plaque erosion is less well defined, but is characterized by the absence of plaque rupture. Histological examination of cases reveals absent endothelium at the site of erosion, leading to exposure of the proteoglycan and smooth muscle cell-rich intima. 1, 4 The exact mechanisms that induce thrombus formation at these sites remain unknown. Virmani et al 4 proposed a third mechanism in the formation of intracoronary thrombi, referred to as calcified nodule in which disruptive nodular calcifications protrude into the lumen and thereby cause thrombosis. The role of calcified nodules in the pathogenesis of coronary events remains unclear. 7 
Vulnerable Plaque
The term vulnerable plaque was introduced by Muller et al 8 in the late 1980s as a coronary plaque with a high susceptibility to rupture. Nowadays, the vulnerable plaque is commonly referred to as a lesion with a high likelihood of precipitating thrombosis. 9 Recently, Stone et al 10 introduced an alternative, more clinically relevant definition of the vulnerable plaque, that is, a plaque that places a patient at risk for future major adverse cardiac events (MACE). However, historically most pathophysiological studies on plaque morphology predisposing to ACS have focused on plaque rupture. A plaque with a large necrotic core and a thin fibrous cap is suspected to be rupture prone and is frequently referred to as a thin-cap fibroatheroma (TCFA). Figure 1 depicts a schematic representation of a suspected vulnerable plaque, including the morphological aspects associated with rupture. These aspects are discussed in detail below.
Morphology Associated With Plaque Rupture
Autopsy studies have shown an inverse relationship between plaque cap thickness and risk of plaque rupture, with 95% of plaque ruptures occurring in lesions with a cap thickness of <65 µm. 11 A postmortem study by Narula et al 12 on 295 coronary atherosclerotic plaques analyzed the importance of various pathological characteristics to differentiate between TCFA and stable plaques and found that fibrous cap thickness was the most accurate discriminator. A large plaque burden with central necrosis negatively affects plaque stability. Expansion of the necrotic core may lead to erosion and subsequent thinning of the fibrous cap. 1 Indeed, autopsy studies have revealed that ruptured plaques are associated with a larger necrotic core when compared with nonruptured plaques. 12, 13 Ruptured caps are more frequently infiltrated by macrophage foam cells than caps of nonruptured TCFA. 13, 14 It is hypothesized that macrophages within the cap play a key role in thinning and, ultimately, cap rupture by secreting proteolytic enzymes such as matrix metalloproteinases. 1, 6, 14, 15 Coronary arteries may respond to plaque growth by expansion or shrinkage of the vessel wall, defined as positive and negative remodeling, respectively. Whereas vulnerable coronary plaques are generally associated with positive remodeling, stable plaques are characterized by negative remodeling of the vessel wall. 16 Although positive remodeling may spare the coronary lumen, continuous outward growth of the plaque will induce neovascularization by microvessels originating from the adventitial vasa vasorum. 17 Unfortunately, these microvessels are suspected to negatively affect plaque stability by causing intraplaque hemorrhage as a result of vascular immaturity and lack of supporting cells. [18] [19] [20] Plaque calcification is associated with all stages of atherosclerosis and can occur as early as during the intimal thickening phase. Microcalcification is thought to be triggered by apoptosis of smooth muscle cells in pathological intimal thickening lesions 21 and by macrophage release of matrix vesicles or by apoptosis within the necrotic core in fibroatheroma lesions. 22 Microcalcification within the thin fibrous cap, or spotty calcification, may serve as a marker of plaque vulnerability. 23, 24 In contrast, larger calcified sheets consisting of merged areas of microcalcification are associated with plaque stability. Whereas microcalcification within the thin fibrous cap and a specific calcification pattern called spotty calcification are reported to be associated with plaque rupture, predominantly calcified plaques with large calcific sheets are thought to be stable plaques.
Challenges to the Vulnerable Plaque Concept
The concept of visualization and treatment of the vulnerable plaque has predominantly focused on plaque rupture, as this is the pathophysiological mechanism most frequently responsible for ACS. 6 A review of literature, which included 22 autopsy studies and a total of 1847 coronary arteries, reported that plaque rupture is observed in 73% of all fatal coronary thrombi. 6 However, contemporary optical coherence tomography studies have provided preliminary evidence that the prevalence of plaque rupture in nonfatal ACS, and especially in non-ST-segment-elevation myocardial infarction (non-STEMI), might be lower. [25] [26] [27] [28] [29] The prevalence of plaque rupture in these studies was reported to be 44% to 73%, whereas plaque erosion and calcified nodule were reported to be only 27% to 33% and 8%, respectively. Although plaque rupture remains the most prominent cause of ACS, it should be noted that novel therapeutics aimed at preventing plaque rupture may have no effect on the incidence of ACS as a result of plaque erosion or calcified nodule.
Another challenge to the concept is the fact that not all cases of intracoronary thrombosis necessarily lead to a clinical event. A recent review by Arbab-Zadeh et al 30 examined the results of many clinical and pathological investigations and reported subclinical plaque rupture in 11.5% of patients with stable CAD and 21.5% in patients who presented with ACS. Subclinical plaque ruptures, however, are not without consequences, as they are considered an important mechanism responsible for increased plaque burden and subsequent lumen narrowing. 31 In line with this hypothesis, Park et al 32 have recently shown that several suspected coronary computed tomographic angiography (CCTA)-derived vulnerable plaque features are correlated with ischemia-causing lesions as defined by an abnormal fractional flow reserve.
The focus on imaging and treatment of specific vulnerable plaques fails to address the fact that atherosclerosis is a systemic, multifactorial disease, and optimal care likely consists of systemic and multifocal diagnosis and therapy, of which local plaque therapy may be a component. 33 In addition, knowledge on the prevalence and natural history of suspected imaging-derived vulnerable features is limited. Longitudinal imaging studies have suggested that plaque morphology may change over time, and many suspected vulnerable plaques may not progress over the course of years and may even regress to more stable lesions. [34] [35] [36] [37] The results and limitations of these studies will be addressed in more detail in their respective sections. Although the identification of rupture prone plaques in vivo will certainly not be able to predict the occurrence of all coronary events, it could provide additional prognostic information to target novel therapeutics. Altogether, lack of clinical outcome studies proving that a suspected vulnerable plaque actually causes a coronary event hampers the clinical applicability of the concept.
Imaging of the Vulnerable Plaque Invasive Techniques
In the past decades, several intracoronary imaging techniques have been developed enabling analysis of in vivo plaque morphology, tissue composition, and even inflammatory activity ( Table 1 ). The clinical potential of these invasive imaging techniques to identify vulnerable plaques will be discussed in this section.
Intravascular Ultrasound
Intravascular ultrasound (IVUS) is performed by use of a catheter harboring a piezoelectric crystal at the distal end, attached to computerized ultrasound equipment. IVUS is based on the reflection of emitted ultrasound waves, according to the acoustic properties of the tissue. 54 Gray scale IVUS is based only on the amplitude of sound waves backscattered from tissue 55 and results in relatively low spatial resolution that hampers detailed plaque characterization. 54 More recently, radiofrequency analysis IVUS has been introduced, of which virtual histology (VH-IVUS) is the most widely available. This technology uses frequency in addition to echo-intensity information to compose an intraluminal image of the coronary artery wall. VH-IVUS can visualize 4 distinct plaque components, that is, fibrous plaque, fibrofatty plaque, necrotic core, and calcium, as shown in Figure 2 . 38, 44, 45 Various ex vivo studies have shown good correlation of these separate components with histology, with predictive accuracy of the various components ranging from 87% to 97%, in dissected coronary arteries during autopsy. [43] [44] [45] [46] On the contrary, no significant correlation between in vivo VH-IVUS-derived necrotic core and histology was found in an atherosclerosis-prone micro pig model. 56 The accuracy of plaque morphology with in vivo VH-IVUS therefore remains a matter of debate.
TCFA can be identified by VH-IVUS in fair good correlation with histology despite an axial resolution (100-200 µm) that limits the visualization of a thin fibrous cap (≤65 µm). 47, 48, 57 VH-derived TCFA (VH-TCFA) is defined as a lesion with a confluent necrotic core (≥10%) plaque in direct contact with the lumen. 48, [58] [59] [60] Three relevant studies have been published on the prognostic value of VH-TCFA. [58] [59] [60] In the PROSPECT study (Providing Regional Observations to Study Predictors of Events in the Coronary Tree), 697 patients with ACS underwent 3-vessel gray scale and VH-IVUS after PCI and were subsequently followed for MACE for a median of 3.4 years. 60 Independent predictors for the occurrence of MACE in nonculprit lesions were VH-TCFA, a small luminal area (≤4 mm 2 ) and a large plaque burden (≥70%). Two other prognostic studies, the VIVA study (Virtual Histology in Vulnerable Atherosclerosis) and the ATHEROREMO-IVUS study (European Collaborative Project on Inflammation and VascularWall Remodeling in Atherosclerosis -Intravascular Ultrasound), incorporating a combined end point of mortality, myocardial infarction (MI), and unplanned revascularization, have confirmed the independent prognostic value of VH-TCFA and a large plaque burden for the occurrence of MACE. 58, 59 Although postmortem studies have shown that large plaque burden is a common feature of ruptured plaques, 61 it should be noted that the combined end points of these studies were mainly driven by unstable or refractory angina, instead of MI and death. Serial IVUS studies have reported conflicting data on the dynamic nature of VH-TCFA over time, with simultaneous development of new VH-TCFA and stabilization of existing lesions. 34, 35 Kubo et al 34 reported that in predominantly patients with stable CAD, after a mean follow-up of 12 months as many as 75% of all VH-TCFA regressed to more stable lesions, whereas only 6% of thick-cap fibroatheroma and 10% of pathological intimal thickening lesions evolved to VH-TCFA. A substudy of the HORIZONS-AMI trial (Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction), on the other hand, showed that in nonculprit lesions in STEMI patients, VH-TCFA remained VH-TCFA in 78% after 13-month follow-up, whereas 49% of thick-cap fibroatheroma and 44% of pathological intimal thickening lesions progressed to VH-TCFA. 35 Patient vulnerability might play a role in the suspected dynamic nature of VH-TCFA. However, variability in the repeat measures of TCFA by VH-IVUS may also be playing a role and the results of VH-IVUS studies on the dynamic nature of TCFA have to be interpreted with caution.
Positive remodeling as defined by gray scale IVUS has been reported to be more common in patients with ACS 41, 42 and at sites with ruptured plaques. 62 However, positive remodeling was not an independent predictor for events in the 3 aforementioned prognostic studies. [58] [59] [60] A recent substudy of the PROSPECT surprisingly reported that both positive and negative remodeling were associated with MACE in nonculprit lesions. 63 Because TCFA was more prevalent in lesions with negative remodeling, this may be presumed as a marker of more advanced atherosclerosis in which subclinical plaque rupture and healing leads to plaque progression. The authors also reported that lesions with positive remodeling more frequently had a large plaque burden (≥70%), when compared with lesions with intermediate or negative remodeling. It is possible that collinearity between a large plaque burden and positive remodeling is responsible for the fact that positive remodeling was not an independent predictor in the previously mentioned outcome studies. [58] [59] [60] IVUS studies have identified a specific pattern of calcification, called spotty calcification, which is thought to be a marker of plaque vulnerability. 24, [64] [65] [66] [67] Spotty calcification on IVUS has been associated with ACS, 24 with ruptured plaques in autopsy studies, 64 and with VH-TCFA and a large necrotic core. 65 A recent comparison between IVUS and histology revealed that IVUS-derived spotty calcification was more frequent in fibroatheroma than in fibrocalcific lesions. 66 Furthermore, a serial IVUS study reported that lesions with spotty calcification had a larger baseline plaque burden and accelerated progression of plaque burden as compared with noncalcified plaques. 67 Other prospective studies are needed to confirm these results. 
Optical Coherence Tomography
In optical coherence tomography (OCT), a low-coherence, infrared light source is directed at the vessel wall, using the backscattered light to produce an image of the tissue. The OCT catheter has an inner imaging core that rotates to provide cross-sectional images from distal to proximal, which can be simplified by an automated pullback system. 68 The resolution of OCT surpasses that of IVUS with an axial resolution of 10 to 20 µm (versus 100-250 µm, respectively), at the cost of a limited depth penetration 0.1 to 2.0 mm (versus 7-10 mm, respectively). OCT has been proposed as an alternative to IVUS in the guidance of PCI procedures, in the ILUMIEN studies, [69] [70] [71] and in the visualization of plaque morphology in vivo. Various postmortem studies have indeed shown good correlation between OCT and histology for the characterization of different types of atherosclerotic plaques. 47, 48, 72, 73 Studies that directly compare the ability of IVUS and OCT to identify histopathologic TCFA have consistently shown better performance of OCT. 47, 48 Recently, hybrid catheters have been developed that combine the high resolution of OCT with the depth penetration of IVUS, 74 with studies suggesting an increase in diagnostic performance. 47, 48 An illustrative overview of the suspected OCT-derived vulnerable plaque features is shown in Figure 3 .
Because of its high spatial resolution, OCT can be used to measure plaque cap thickness and to truly identify TCFA. 51 The identification of TCFA by OCT is in part hampered by the limited depth penetration of OCT and the consequent limitations in establishing lipid pools. Furthermore, light scattering in calcified and even fibrous plaques has been reported to cause misdiagnosis of lipid pools on OCT. 75 Although large prospective OCT studies with clinical follow-up are lacking, OCT-derived TCFA is shown to correlate with clinical presentation. Various studies have demonstrated that TCFA is more commonly found in patients presenting with ACS than in those presenting with stable angina pectoris 76, 77 and cap thickness is thinner in culprit than in nonculprit lesions. 76, 77 The definition of OCT-derived TCFA, however, is not unambiguous. Many studies have used 65 µm as cutoff for TCFA, based on postmortem histology studies. 4, 29, 47, 74, 76, 77 Nonetheless, both recent in and ex vivo OCT studies have shown that nearly all ruptured plaques have a cap thickness of <80 to 85 µm 12,78 and in a direct postmortem comparison of OCT and histology, Brown et al 48 identified a fibrous cap thickness of ≤85 μm over 3 continuous frames to be the optimal definition for the identification of histopathologic TCFA. This discrepancy between OCT and postmortem histology might be explained by tissue shrinkage occurring during tissue preparation. 39 Furthermore, some studies have used an additional parameter to define TCFA. The arc of the lipid pool has to be large, as a surrogate for a large necrotic core, with a frequently used cutoff of ≥90°. 77, 79, 80 The aforementioned study by Brown et al 48 reported a maximum arc of the lipid pool of ≥80° to be the optimal cutoff for the identification of TCFA. The latest OCT consensus statement stated that the cutoffs for cap thickness should be related to histopathology and should be adjusted to account for tissue shrinkage and that the number of quadrants of the arc of the lipid pool defining a TCFA remains an unanswered question. 39 Prospective OCT studies with clinical follow-up to validate the definition of OCT-derived TCFA are warranted.
Macrophage infiltration of the thin fibrous cap is thought to be an important feature of the vulnerable plaque. 12 Macrophages appear on OCT as so-called bright spots with a high signal attenuation behind it. 39 Tearney et al 53 reported excellent correlation between quantification of bright spots and macrophage density in carotid artery plaques. This was confirmed in coronary artery plaques by a recent postmortem study on coronary artery plaques by Di Vito et al. 52 Further studies showed that macrophage density is greater in TCFA than in non-TCFA, 81 greater in culprit than in nonculprit plaques, 82 and greater STEMI patients than in stable angina patients. 83 It should be noted, however, that to a lesser degree, other structures such as cellular fibrous tissue and cholesterol clefts may also appear as bright spots on OCT, thereby mimicking macrophage infiltrates. 84 Vaso vasorum and micro vessels within coronary atherosclerotic plaques can be visualized by OCT, appearing as microchannels. 85, 86 Several reports have shown a correlation between the density of microchannels in OCT and plaque vulnerability (defined as TCFA) 79, 80, 87 and increase in plaque volume. 88 
Near-Infrared Spectroscopy
In near-infrared spectroscopy (NIRS), a scanning laser delivers near-infrared light to the tissue of interest and the proportion of light reflected back is measured over the range of optical wavelength by a detector. Cholesterol has specific features in the wavelength region of NIRS, allowing distinct imaging of a lipid core plaque (LCP). 40 The measured data are displayed as a chemogram, a 2-dimensional visualization of the probability of the presence of an LCP per millimeter. NIRS data can also be used to calculate a lipid core burden index (LCBI), which is the amount of lipid in a scanned artery. LCBI 4mm is commonly used to represent the amount of lipid in a coronary segment of 4 mm length. Gardner et al 49 confirmed the ability of NIRS 89 A typical example of NIRS findings in a STEMI culprit lesion is depicted in Figure 4 .
NIRS alone, however, is limited by its inability to provide information about the lumen and plaque depth. Therefore, NIRS is commonly combined with IVUS in a combined NIRS-IVUS catheter, in which both techniques can be acquired simultaneously in 1 pullback. Multiple postmortem studies have compared the ability of NIRS and gray scale IVUS alone versus combined NIRS-IVUS to identify fibroatheroma and showed that combined NIRS-IVUS was superior to NIRS or IVUS alone. 90, 91 In vivo studies have shown that with NIRS-IVUS, LCBI 4mm with a cutoff of >400 was able to identify culprit lesions in patients with STEMI, 92 non-STEMI, and unstable angina. 93 A recent prospective observational study investigated the prognostic value of NIRS in nonculprit vessels in patients with ACS or stable angina referred for PCI. The authors found that LCBI above the median was a significant predictor for the occurrence of mortality, nonfatal ACS, stroke, and unplanned revascularization within 1-year follow-up. 94 Although analysis was done on a patient level, a high LCBI might be an important feature of the suspected vulnerable plaque. Two prospective trials examining the natural history of nonculprit lesions with high LCBI at NIRS are currently enrolling patients, that is, the PROSPECT II trial (NCT02171065) and the LRP study (NCT02033694).
Noninvasive Imaging
Next to invasive imaging modalities, CCTA, positron emission tomography (PET), and magnetic resonance imaging (MRI) have emerged as possible noninvasive alternatives to visualize the vulnerable plaque. The characteristics of these imaging modalities are summarized in Table 2 and will be discussed in this section.
Coronary Computed Tomographic Angiography
CCTA is a widely available noninvasive imaging tool with a relatively high spatial resolution that allows visualization of different components of the vulnerable plaque, 95 as is illustrated in Figure 5 .
In accordance with autopsy and IVUS, positive remodeling is a suspected feature of CCTA-derived plaque vulnerability. [98] [99] [100] 102 In a direct comparison between CCTA and VH-IVUS, Kröner et al 99 reported that plaques with positive remodeling had larger necrotic cores and were more frequent VH-TCFA than plaques without positive remodeling. Furthermore, a recent meta-analysis by Thomsen et al 98 showed that the remodeling index was higher in patients with ACS than in patients with stable angina and in culprit lesions versus nonculprit lesions. CCTA uses CT attenuation, expressed in Hounsfield Units, to differentiate between calcified plaques with higher attenuation and partially-and noncalcified plaques with lower attenuation. Low-attenuation plaques (LAP) have been shown to correlate with lipid-rich plaques assessed by VH-IVUS. 101, 103, 109 Furthermore, studies that compare CCTA with OCT have reported that both positive remodeling and LAP were associated with OCT-derived TCFA 102 and OCTderived TCFA with macrophage infiltration. 100 However, many studies report important overlap in CT densities between lipidrich and fibrous plaques, thus somewhat limiting the ability of CT attenuation to reliably identify lipid-rich plaques. 101, 103, 109 As in IVUS studies, 24, [64] [65] [66] [67] some CCTA studies have suggested that not only LAP, but also plaques with spotty calcification might be considered vulnerable. [110] [111] [112] The aforementioned meta-analysis by Thomsen et al 98 reported that plaques with spotty calcification were associated with ACS rather than stable angina and with culprit rather than with nonculprit lesions. Furthermore, CCTA-derived spotty calcification has been shown to correlate well with IVUS-derived spotty calcification 107 and is shown to correlate with VH-TCFA and a large necrotic core on IVUS. 108 The napkin-ring sign is an additional suspected CT feature of plaque vulnerability and represents a necrotic core with low attenuation surrounded by a ring-like area of higher attenuation. [113] [114] [115] [116] [117] Recent autopsy studies on human donor hearts confirmed the presence of a large necrotic core in plaques with a napkin-ring sign 113 and showed excellent diagnostic accuracy of the napkin-ring sign for TCFA. 114 Studies comparing OCT and CCTA have reported conflicting results on the value of the CCTA napkin-ring sign. 100, 115, 117 Some studies reported a correlation between napkin-ring sign and OCT-derived TCFA, 115, 117 whereas a recent study by Nakazato et al 100 showed no correlation between the napkin-ring sign and TCFA with macrophage infiltration.
To evaluate the prognostic value of the suspected CT features of the vulnerable plaque, studies on the natural history of these components are needed. The first prospective observational study by Motoyama et al 118 studying the prognostic value of LAP, positive remodeling and spotty calcification reported that both LAP and positive remodeling at CCTA were independent predictors for the occurrence of MACE in short-term follow-up, whereas spotty calcification was not. Motoyama et al 36 recently confirmed the prognostic value of LAP and positive remodeling in the same cohort for the mid-term follow-up (3.9±2.4 years). Furthermore, a prospective study with 895 patients and a mean follow-up of 2.3 years, reported that the napkin-ring sign in addition to LAP and positive remodeling, was independently associated with a composite end point of ACS and cardiac death. 116 However, because these studies used MACE on a patient level as outcome, the events did not necessarily correlate with the specific CCTA-derived vulnerable plaque. Although LAP, positive remodeling, and the napkin-ring sign appear as important features of CT-derived plaque vulnerability, the impact of spotty calcification remains somewhat unclear.
Limited studies with serial CCTA imaging have evaluated the natural history of the suspected CCTA-derived vulnerable plaque. 36, 37 In the previously mentioned study by Motoyama et al, 36 423 patients with serial CCTA imaging after a median of 4.1 years were included for analysis. The authors reported that of all patients with high-risk plaques at baseline, which was defined by either positive remodeling or LAP, 93% had high-risk plaques at follow-up and 7% of non-high-risk plaques progressed to highrisk plaques at follow-up. Furthermore, patients with serial CCTA imaging in the PROSPECT study showed an increase in plaque volume over time accommodated by expansive remodeling. 37 The ongoing multicenter PARADIGM study (Progression of Atherosclerotic Plaque Determined by Computed Tomographic Angiography Imaging) will include 5000 patients and perform serial CCTA after 2 years to assess the natural history of coronary plaques on CCTA over time (NCT02803411).
The added value of CCTA imaging of suspected vulnerable plaques has also been demonstrated in patients presenting with acute chest pain.
111, 119 Kristensen et al 119 reported that in patients with non-STEMI, the amount of noncalcified plaque volume in nonobstructive lesions was an independent predictor for the occurrence of MACE during follow-up. The ROMICAT-II trial (Rule Out Myocardial Ischemia/Infarction Using Computer Assisted Tomography) investigated patients presenting to the emergency room with acute chest pain but negative initial electrocardiography and troponin by CCTA imaging. The presence of any of the suspected vulnerable plaque features was an independent predictor for the presence of ACS. 111 CCTA might have a role in establishing both the diagnosis and the prognosis in patients with ACS.
Plaque quantification and characterization by automated software has been proposed to increase prognostic value of CCTA in recent years, and studies have shown good correlation with VH-IVUS quantitative measures. 101, 103 Furthermore, coronary plaques labeled lipid-rich and positive remodeled by automated software are reported to be more frequent in non-STEMI than in patients with stable angina. 120 Versteylen et al 121 have recently demonstrated that a semiautomated approach in which plaques are manually identified followed by automatic characterization and quantification provided incremental prognostic value to conventional CT reading for the occurrence of MACE.
Positron Emission Tomography
Although widely used in oncology for several decades, 18 F-fluorodeoxyglucose ( 18 F-FDG) and 18 F-sodium fluoride ( 18 F-NaF) have only recently been proposed in the imaging of atherosclerosis. 18 F-FDG is a radiolabeled glucose analogue, and its uptake determined by PET imaging can be used as a surrogate for metabolic activity. 96 18 F-FDG uptake has been linked with increased plaque macrophage density in animal models 122, 123 and in human carotid arteries after endarterectomy 105 and is considered to be a marker of plaque inflammation and vulnerability. The use of 18 F-FDG imaging in CAD is, however, limited by the high background 18 F-FDG uptake caused by the glucose metabolism of the myocardium. Studies on FDG imaging of the coronary arteries have therefore shown conflicting results. [124] [125] [126] Rogers et al 124 reported that in a group of 25 patients, FDG uptake was significantly higher in culprit lesions in ACS than in lesions stented for stable CAD. Although the results were in line with findings from Cheng et al 126 in a similar population, a more recent study on 40 patients with acute MI showed no difference in uptake between culprit lesions and nonculprit lesions. 125 18 F-NaF is a PET tracer that detects areas of microcalcification by binding to hydroxyapatite and is not hampered by uptake in the myocardium. 106 Unlike macrocalcification, which can be visualized by CT, these microcalcifications are considered an important feature of the vulnerable plaque. 22 The prognostic value of 18 F-NaF uptake was recently confirmed in a prospective study that showed that 18 F-NaF uptake was higher in culprit lesions than in nonculprit lesions in patients after MI and in patients with symptomatic carotid artery disease. 125 Furthermore, 18 F-NaF uptake showed a trend for the identification of TCFA on intravascular ultrasound (P=0.068). Recently, preclinical and early clinical data have proposed the use of several PET tracers that target macrophages for the imaging of atherosclerosis. 68Ga-DOTATATE is a PET tracer that targets upregulated somatostatine receptor 2 in macrophages, and its uptake is reported to be colocalized with macrophage-rich plaques in an atherosclerotic mouse model. 127 In humans, the uptake of 68Ga-DOTATATE has been associated with coronary calcification and clinical risk profile. 128 Another macrophage targeted tracer 11C-PK11195, a selective ligand of the translocator protein highly expressed on macrophages, has been reported to have increased uptake in carotid plaques in patients with symptomatic carotid artery disease. 129 Furthermore, 18 F-galacto-RGD is a PET tracer that specifically binds integrin alpha(v)beta(3), which is expressed by macrophages and endothelial cells in atherosclerotic lesions. An early clinical study reported accumulation of this tracer in obstructive carotid atherosclerosis. 130 Further translational studies are needed to clarify the ability of these tracers to target suspected vulnerable plaques.
Magnetic Resonance Imaging
MRI has been widely used in carotid artery disease to differentiate between plaque components and to study high-risk plaque features. 131 The identification of intraplaque hemorrhage, lipid core, fibrous tissue components, and calcification can be achieved by the use of several MRI image techniques, that is, pre-and post-contrast T1-weighted, T2-weighted, proton-density, and time-of-flight imaging. The use of MRI in coronary arteries however is limited by its relatively low spatial resolution and by cardiac and respiratory motion. Despite these limitations, the use of MRI has shown some potential in CAD. 104 A postmortem study on 28 plaques obtained from human donor hearts has reported an excellent correlation of ex vivo T1-weighted, T2-weighted, and ultrashort echo time MRI with histology for the identification of calcified and lipid-rich coronary plaques. 104 Several studies have investigated the potential of T1-weighted imaging coregistered with magnetic resonance angiography in patients with CAD. [132] [133] [134] [135] High signal intensity on T1-weighted images is reported to be a marker for intraplaque hemorrhage and intracoronary thrombus and is shown to be associated with IVUS-derived positive remodeling, 132 with low CT-attenuation 132 and with OCT-derived intracoronary thrombus, 133 ,135 macrophage accumulation, 134 lipid-rich plaque, plaque rupture, and TCFA. 135 Noguchi et al 97 prospectively studied 650 patients with suspected or known CAD and showed that high-intensity plaques on T1-weighted images were associated with a worse MACEfree survival on a patient level. There are currently no data on the ability of T1-weighted MRI to identify lesion-specific MACE.
As mentioned previously T2-weighted, proton-density, and time-of-flight imaging are used next to T1-weighted images in carotid artery disease to differentiate between plaque components. Studies that report on the value of these techniques in CAD are limited to animal studies and case reports. In a porcine model of coronary balloon injury, T2-weighted imaging enabled detection of coronary vessel wall edema in good correlation with histology. 136 Further studies are needed to evaluate the role of the various MRI techniques in the visualization of the suspected vulnerable plaque.
Treatment of Vulnerable Plaques Local Therapy
Current management guidelines focus on identifying and revascularizing obstructive coronary stenoses that cause a hemodynamically significant reduction in coronary blood flow. 137, 138 Despite extensive validation of this flow-limiting-guided revascularization strategy in large prospective randomized trials, such as the FAME and DEFER trials (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation; Deferral of Percutaneous Coronary Intervention), 139, 140 the event rate after complete revascularization remains relatively high with MACE occurring in ≈30% of patients after 5 years (FAME trial). 139 Serial angiography studies have shown that, although plaques leading to ACS are frequently flow limiting, coronary lesions with initially mild stenosis often rapidly progress in the weeks to months before an ACS. 141 As discussed in the previous section, different aspects of plaque vulnerability are shown to have independent prognostic value for the occurrence of MACE and might be used to improve risk stratification and guide personalized therapy.
The PRAMI study (Preventive Angioplasty in Myocardial Infarction Trial) reported a reduced risk of adverse cardiovascular events after revascularization of residual CAD in STEMI patients after primary PCI of infarct artery. 142 Given that ≈35% of intermediate lesions are hemodynamically significant, 143 sealing of nonobstructive vulnerable plaques is a potential explanation of improved outcome in the PRAMI study. However, no definite evidence exists that this is indeed the mechanism responsible for the improved outcome. The first-in-human trial of attempted sealing of nonobstructive high-risk plaques was the SECRITT trial (vShield Evaluated at Cardiac Hospital in Rotterdam for Investigation and Treatment of TCFA). In this trial, a nitinol selfexpanding stent was implanted in a nonobstructive VH-TCFA with thin-cap at OCT in 13 patients and revealed recovery of neocap thickness without complications at 6-month followup. 144 Instead of placing a traditional bare-metal stent, the use of a bioabsorbable vascular scaffold (BVS) may avoid long-term detrimental effects such as late stent thrombosis, by dissolving ultimately and facilitating restoration of normal coronary physiology. Implantation of an everolimus-eluting BVS in a porcine coronary artery model showed complete dissolution of the struts after 3 years by both OCT and histology and showed a fibromuscular neointima covering the plaque. 145 In an in-human study, Brugaletta et al 146 revealed formation of a thick neointima in 58 patients who received an ABSORB BVS, with a mean neointima thickness of 210 µm after 6 months and 220 µm after 12 months. A recent post hoc analysis, using data from the ABSORB cohort B trial, the SECRITT trial and the Svelte first-in-man trial evaluated changes in plaque morphology after BVS and bare-metal stent implantation. 147 Serial OCT showed development of a neointima over TCFA, both after BVS and bare-metal stent implantation, thus sealing the plaque and transforming the TCFA to a thickcap fibroatheroma. Furthermore, after BVS implantation the neointima development continued after short-term follow-up without compromising luminal dimensions, whereas neointima formation after bare-metal stent placement caused reduction in luminal dimensions and ceased after 6 months. Although evidence is limited, these findings suggest the feasibility of BVS to seal nonobstructive vulnerable plaques. Currently, 3 randomized trials that address this issue are including patients (Table 3) .
The PROSPECT-ABSORB (Multicentre Prospective Natural History Study Using Multimodality Imaging in Patients With Acute Coronary Syndromes Combined With a Randomized, Controlled, Intervention Study) will randomize patients after STEMI/non-STEMI with residual nonobstructive lesions and vulnerability as assessed by IVUS to either BVS implantation with optimal medical therapy or optimal medical therapy only (NCT02171065). The PECTUS (Pre-Emptive, OCT Guided Angioplasty of Vulnerable, Intermediate Coronary Lesions: A Randomized Trial) trial has a similar study design although it will incorporate OCT as a gatekeeper for the detection of plaque vulnerability (NTR5590). The PREVENT study (The Preventive Implantation of Bioresorbable Vascular Scaffold on Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics) will use IVUS, NIRS, and OCT to assess plaque vulnerability and guide BVS implantation (NCT02316886). These trials will likely shed light on this much-debated topic. Potentially, future coronary revascularization strategies may not only be dictated by hemodynamic significance of coronary stenoses but also plaque composition and subsequent risk of rupturing.
Systemic Therapy
Although local treatment of an individual vulnerable plaque is appealing, it fails to address the fact that atherosclerosis is a systemic disease. Various systemic therapies have been proposed to reduce plaque vulnerability (Table 4) .
LDL-Lowering Drugs
The mortality benefit of LDL-lowering therapy by use of statins is well established, 151 and its use in patients with CAD is advocated by current guidelines. 137, 138 In addition to their lipid-lowering properties, statins are reported to possess pleotropic effects, that is, enhancement of endothelial function and decrease of oxidative stress and inflammation. 166 The effects of statins on coronary plaque progression in vivo have been investigated by various imaging modalities. Serial CCTA studies have shown that initiation of statin therapy reduces progression of noncalcified plaque volume [167] [168] [169] and even progression in LAP volume. 167 Furthermore, a recent trial randomized patients between high-intensity and standard statin therapy showed increase in dense calcium volume, implicating possible plaque stabilization. 170 Several serial IVUS studies have shown that high-intensity statin therapy induces regression in plaque burden. [171] [172] [173] This was recently confirmed by a post hoc analysis including data from 3495 patients. 150 In addition to reduction of plaque burden, the authors reported that statin therapy induces plaque calcification, which is associated with plaque stabilization. 150 Kataoka et al 174 published pooled data from 8 clinical trials on the beneficial effect of statins in IVUS-derived high-risk plaques (large atheroma volume, positive remodeling, and spotty calcification). The authors reported that atheroma regression was highest in patients with high-risk plaques, suggesting a plaque-stabilizing effect of statin therapy. This is supported by findings from OCT studies. 148, 149 Kataoka et al 148 reported that high-intensity statin therapy in patients with stable CAD is associated with less vulnerable plaque features on OCT, that is, thicker fibrous cap and smaller lipid arc. Furthermore, the EASY-FIT study (Effect of Atorvastatin Therapy on Fibrous Cap Thickness in Coronary Atherosclerotic Plaque as Assessed by Optical Coherence Tomography) showed that in patients with unstable angina high-intensity statin therapy provided greater increase in fibrous cap thickness than low-intensity statin therapy. 149 Because this increase in cap thickness was associated with decrease in inflammatory biomarkers, it is believed that in addition to the LDL-lowering action, anti-inflammatory effects of statin therapy may influence plaque vulnerability.
The IMPROVE-IT trial (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) 154 with a total number of 18 144 patients showed a reduction in adverse cardiac events in patients on ezetimibe and simvastatin versus simvastatin only and paved the way for the introduction of ezetimibe into treatment guidelines. 138 A randomized clinical trial with serial IVUS imaging showed that combination therapy of ezetimibe and statin was correlated with negative vessel remodeling and produced stronger coronary plaque regression than statin therapy alone. 152 A small single-center randomized study showed that addition of ezetimibe to fluvastatin resulted in a larger increase in fibrous cap thickness measured by OCT. 153 Recently, a novel class of LDL-lowering drugs called proprotein convertase subtilisin-kexin type 9 inhibitors has emerged.
Proprotein convertase subtilisin-kexin type 9 (PCSK9) binds to the LDL receptor leading to destruction of the receptor and thereby preventing the recirculation of LDL receptor to the hepatocyte cell surface. Through the inhibition of PCKS9, these novel drugs significantly reduce LDL cholesterol levels when added to statin therapy. 175 PCKS9 levels are linearly associated with necrotic core size of plaques in nonculprit coronary arteries. 176 The impact of PCSK9 inhibition on plaque vulnerability remains to be elucidated, but 1 PCKS9 inhibtor, alirocumab, is reported to reduce plaque macrophage and necrotic core content in a mouse model of atherosclerosis. 177 The recently published GLAGOV trial (Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound) reported a reduction in IVUS-derived plaque atheroma volume in patients treated with evolocumab for 78 weeks. 155 In a post hoc analysis of the ODYSSEY LONG TERM study (Long-term Safety and Tolerability of SAR236553 [REGN727] in High Cardiovascular Risk Patients With Hypercholesterolemia Not Adequately Controlled With Their Lipid Modifying Therapy: A Randomized, Double-Blind, Placebo-Controlled Study), addition of a PCKS9 inhibitor to statin therapy resulted in better MACE-free survival (defined as death from coronary heart disease, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization). 178 Larger prospective clinical trials with hard clinical end points are currently enrolling and will provide more information on the added value of proprotein convertase subtilisin-kexin type 9 inhibition.
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Anti-Inflammatory Drugs
Inflammation plays a key role in plaque formation and vulnerability. 179, 180 Several anti-inflammatory therapies have been HMG-CoA indicates 3-hydroxy-3-methylglutaryl-coenzyme A; HR, hazard ratio; IL-1β, interleukine-1β; IVUS, intravascular ultrasound; LDL, low-density lipoprotein; Lp-PLA2, lipoprotein-associated phospholipase A2; MACE, major adverse cardiac events; MI, myocardial infarction; NA, not available; NPC1L1, Niemann-Pick C1-like 1; OCT, optical coherence tomography; PCSK9, proprotein convertase subtilisin/kexin type 9; and RR, relative risk.
*Meta-analysis of 26 randomized trials showing reduction in major vascular events. †Reduction in primary composite end point of death from cardiovascular causes, major coronary event, or nonfatal stroke. ‡Darapladib: no reduction in composite end point of cardiovascular death, myocardial infarction (urgent revascularization), or stroke. §Varespladib: increase in the secondary end point of myocardial infarction at interim analysis. ‖Reduction in composite end point of acute coronary syndrome, out-of-hospital cardiac arrest, or noncardioembolic ischemic stroke.
proposed to reduce atherosclerotic burden and stabilize coronary plaques. 181 Lipoprotein-associated phospholipase A2 is an enzyme produced and secreted by inflammatory cells centrally involved in atherosclerosis and is highly expressed in the necrotic core of atherosclerotic plaques. 182 Lipoprotein-associated phospholipase A2 inhibition has been proposed as a therapeutic agent targeting the vulnerable plaque. Although a randomized placebo controlled trial reported a reduction in IVUS-derived necrotic core development, 159 large randomized trials on the benefit of lipoprotein-associated phospholipase A2 inhibitors on clinical end points have to date been negative. [160] [161] [162] Methotrexate is a folic acid antagonist with anti-inflammatory actions and is used for the treatment of several autoimmune disorders. A large meta-analysis of observational studies in patients receiving low-dose methotrexate for psoriasis and rheumatoid arthritis showed a reduction in cardiovascular events. 183 The CIRT (Cardiovascular Inflammation Reduction Trial) was designed to investigate the ability of low-dose methotrexate to prevent future coronary events in patients after MI. 163 The anti-inflammatory activity of colchicine is used in the treatment of inflammatory conditions such as gout, pericarditis, and familial Mediterranean fever. Retrospective studies have shown indirect support for the use of colchicine in atherosclerosis by reporting lower prevalence of MI in colchicine-treated patients having gout 184 and familial Mediterranean fever. 185 This was confirmed by the LoDoCo trial (Low-Dose Colchicine), a randomized placebo controlled trial with 532 patients with stable CAD and median follow-up of 3 years, showing improved MACE-free survival in patients treated with colchicine. 164 The LoDoCo-2 trial will investigate the effects of colchicine in 3000 patients over 3 years and is scheduled to be completed in 2019 (ACTRN12614000093684).
Canakinumab is a monoclonal antibody that selectively neutralizes interleukin-1β, a proinflammatory cytokine that plays multiple roles in atherosclerosis and rupture prone plaques. 186 A recent phase IIb trial with 556 patients has shown that subcutaneous injection of canakinumab is well tolerated and reduces different biomarkers of inflammation, that is, C-reactive protein, interleukin-6 and fibrinogen. 187 The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcomes Study) has finalized enrollment of 10 120 patients and is awaiting follow-up to report on the possible reduction of recurrent MACE by canakinumab in patients after MI. 165 
Conclusions and Future Perspectives
Recent advances in invasive and noninvasive imaging modalities have improved the potential for early and accurate identification of vulnerable coronary plaques. Although several imaging studies have been published on the natural history of suspected vulnerable coronary plaques, more evidence is warranted to establish the prognostic value of the various invasive and noninvasive plaque characteristics. Novel applications of invasive imaging modalities such as IVUS, OCT, and NIRS have paved the way for the evaluation of therapeutic agents specifically targeted at reducing plaque vulnerability. In the future, reliable noninvasive imaging modalities are crucial for the detection and treatment of vulnerable plaque in larger and lower risk populations. Preliminary data have shown potential for pre-emptive local treatment of vulnerable coronary plaques with PCI, and this strategy is currently being investigated in the PROSPECT-ABSORB, the PECTUS trial, and the PREVENT. Statin therapy has been shown to induce plaque stabilization and lead to a significant reduction in cardiovascular events. The effects of other systemic, mostly anti-inflammatory, drug therapies on cardiovascular outcome are currently being studied in large clinical trials. Results from these studies may guide in proper decision making pertaining the management of vulnerable plaques in patients with MI to prevent future ACS. Nonetheless, an era of personalized treatment for patients with CAD seems both inevitable and indispensable.
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